FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204990173> ?p ?o ?g. }

• W3204990173 abstract "Psoriasis is a chronic immune-mediated inflammatory skin disease for which biologics are effective treatments. Dose reduction (DR) of the first generation biologics seems a promising way for more efficient use of expensive biologics. A substantial part of patients on tumor necrosis factor (TNF)-alfa inhibitors and ustekinumab could successfully lower their dose, after following a tightly controlled DR strategy. The objective of this study is to assess whether controlled DR of interleukin (IL)-17 and IL-23 inhibitors in psoriasis patients with low disease activity is non-inferior (NI) to usual care (UC).This is an international, prospective, multicenter, pragmatic, randomized, non-inferiority trial. A total of 244 patients with stable low disease activity (Psoriasis Area and Severity Index (PASI) ≤ 5) for at least 6 months and using secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, or tildrakizumab in the standard dose, together with stable low disease activity, defined as a PASI ≤ 5 and Dermatology Life Quality Index (DLQI) ≤ 5 at the moment of inclusion, will be randomized 2:1 to DR or UC. In the DR group, dosing intervals will be prolonged stepwise to achieve 66% and 50% of the original dose. Disease activity is monitored every 3 months by PASI and DLQI. In case of disease flare (i.e., PASI and/or DLQI increase), treatment is adjusted to the previous effective dose. The primary outcome is the incidence proportion of persistent flares (PASI > 5 for ≥ 3 months), which will be compared between arms. Secondary outcomes include proportion of patients with successful DR, (course of) PASI and DLQI, serious adverse events (SAEs), health-related quality of life, costs, and pharmacokinetic profile. Outcomes of DR will be compared to UC.With this study, we aim to assess whether DR of IL-17 and IL-23 inhibiting biologics can be achieved for psoriasis patients with low disease activity, without losing disease control. Reducing the dose may lead to more efficient use of biologics.ClinicalTrials.gov NCT04340076 . Registered on April 9 2020." @default.
• W3204990173 created "2021-10-25" @default.
• W3204990173 creator A5000467702 @default.
• W3204990173 creator A5011017049 @default.
• W3204990173 creator A5026245811 @default.
• W3204990173 creator A5042761133 @default.
• W3204990173 creator A5044485746 @default.
• W3204990173 creator A5045658215 @default.
• W3204990173 creator A5082636128 @default.
• W3204990173 date "2021-10-16" @default.
• W3204990173 modified "2023-10-14" @default.
• W3204990173 title "Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study" @default.
• W3204990173 cites W1932535307 @default.
• W3204990173 cites W1990166011 @default.
• W3204990173 cites W2001952429 @default.
• W3204990173 cites W2030298480 @default.
• W3204990173 cites W2042872568 @default.
• W3204990173 cites W2043913413 @default.
• W3204990173 cites W2048370747 @default.
• W3204990173 cites W2050172669 @default.
• W3204990173 cites W2080165152 @default.
• W3204990173 cites W2096991001 @default.
• W3204990173 cites W2122506300 @default.
• W3204990173 cites W2128659393 @default.
• W3204990173 cites W2149148432 @default.
• W3204990173 cites W2152740900 @default.
• W3204990173 cites W2158916543 @default.
• W3204990173 cites W2171689947 @default.
• W3204990173 cites W2276035339 @default.
• W3204990173 cites W2418506270 @default.
• W3204990173 cites W2528727153 @default.
• W3204990173 cites W2570140560 @default.
• W3204990173 cites W2606035821 @default.
• W3204990173 cites W2613958818 @default.
• W3204990173 cites W2620974275 @default.
• W3204990173 cites W2623211590 @default.
• W3204990173 cites W2789656381 @default.
• W3204990173 cites W2800010837 @default.
• W3204990173 cites W2895932838 @default.
• W3204990173 cites W2945527657 @default.
• W3204990173 cites W2971816470 @default.
• W3204990173 cites W3006361551 @default.
• W3204990173 cites W3017244954 @default.
• W3204990173 cites W3103233798 @default.
• W3204990173 cites W3107342060 @default.
• W3204990173 cites W3117231578 @default.
• W3204990173 cites W4292806894 @default.
• W3204990173 doi "https://doi.org/10.1186/s13063-021-05681-z" @default.
• W3204990173 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8520290" @default.
• W3204990173 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34656148" @default.
• W3204990173 hasPublicationYear "2021" @default.
• W3204990173 type Work @default.
• W3204990173 sameAs 3204990173 @default.
• W3204990173 citedByCount "7" @default.
• W3204990173 countsByYear W32049901732022 @default.
• W3204990173 countsByYear W32049901732023 @default.
• W3204990173 crossrefType "journal-article" @default.
• W3204990173 hasAuthorship W3204990173A5000467702 @default.
• W3204990173 hasAuthorship W3204990173A5011017049 @default.
• W3204990173 hasAuthorship W3204990173A5026245811 @default.
• W3204990173 hasAuthorship W3204990173A5042761133 @default.
• W3204990173 hasAuthorship W3204990173A5044485746 @default.
• W3204990173 hasAuthorship W3204990173A5045658215 @default.
• W3204990173 hasAuthorship W3204990173A5082636128 @default.
• W3204990173 hasBestOaLocation W32049901731 @default.
• W3204990173 hasConcept C126322002 @default.
• W3204990173 hasConcept C16005928 @default.
• W3204990173 hasConcept C168563851 @default.
• W3204990173 hasConcept C2776173921 @default.
• W3204990173 hasConcept C2776260265 @default.
• W3204990173 hasConcept C2777011040 @default.
• W3204990173 hasConcept C2778975655 @default.
• W3204990173 hasConcept C2779134260 @default.
• W3204990173 hasConcept C2779745271 @default.
• W3204990173 hasConcept C2779786854 @default.
• W3204990173 hasConcept C2780132546 @default.
• W3204990173 hasConcept C2780564577 @default.
• W3204990173 hasConcept C71924100 @default.
• W3204990173 hasConceptScore W3204990173C126322002 @default.
• W3204990173 hasConceptScore W3204990173C16005928 @default.
• W3204990173 hasConceptScore W3204990173C168563851 @default.
• W3204990173 hasConceptScore W3204990173C2776173921 @default.
• W3204990173 hasConceptScore W3204990173C2776260265 @default.
• W3204990173 hasConceptScore W3204990173C2777011040 @default.
• W3204990173 hasConceptScore W3204990173C2778975655 @default.
• W3204990173 hasConceptScore W3204990173C2779134260 @default.
• W3204990173 hasConceptScore W3204990173C2779745271 @default.
• W3204990173 hasConceptScore W3204990173C2779786854 @default.
• W3204990173 hasConceptScore W3204990173C2780132546 @default.
• W3204990173 hasConceptScore W3204990173C2780564577 @default.
• W3204990173 hasConceptScore W3204990173C71924100 @default.
• W3204990173 hasFunder F4320321007 @default.
• W3204990173 hasFunder F4320336788 @default.
• W3204990173 hasIssue "1" @default.
• W3204990173 hasLocation W32049901731 @default.
• W3204990173 hasLocation W32049901732 @default.
• W3204990173 hasLocation W32049901733 @default.
• W3204990173 hasLocation W32049901734 @default.
• W3204990173 hasLocation W32049901735 @default.
• W3204990173 hasLocation W32049901736 @default.

• next